Related Experiment Video
Updated: Apr 29, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Treatment of metastatic breast cancer
1Presented by William J. Gradishar, MD, Betsy Bramsen Professor of Breast Oncology, Division of Hematology and Medical Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Abstract:
Many newer agents in combination are being studied in the front-line treatment of women with HER2-positive metastatic breast cancer (MBC), but the story in the endocrine arena is more about the wise use of new strategies to overcome endocrine resistance, because no new antihormonal agents have been approved in the past decade. During his presentation at the NCCN 19th Annual Conference, Dr. William Gradishar explored what's new in the treatment of MBC, focusing primarily on enhancing the effect of endocrine therapy to overcome resistance with newer targeted agents such as everolimus, reevaluating the role of rebiopsy on disease progression and measuring circulating tumor cells as a surrogate of response to treatment, and reviewing the effective treatment regimens for HER2-positive disease.
Insights
New strategies enhance endocrine therapy for metastatic breast cancer (MBC) by overcoming resistance. Research focuses on targeted agents like everolimus and assessing biomarkers for treatment response.
Area of Science:
- Oncology
- Medical Sciences
Background:
- The endocrine treatment landscape for metastatic breast cancer (MBC) lacks novel antihormonal agents approved in the last decade.
- Focus is shifting towards enhancing existing endocrine therapy efficacy to combat resistance.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Metastasis
Treatment Resistent Cancers
Treatment Resistant Cancers

